Biotech News

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

SOLIGENIX (SNGX)SOLIGENIX2026-04-02 11:30 ESTCompany update

SNGX (SNGX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is sngx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

SNGXSOLIGENIX2026-04-28 11:30 EST

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

SNGXSOLIGENIX2026-03-23 11:30 EST

HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026

CLDXCelldex Therapeutics2026-06-14 09:15 EST

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

CLDXCelldex Therapeutics2026-06-14 14:21 EST

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

BMYBMYBristol-Myers Squibb Company2026-03-20 20:42 EST

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

ENTAEnanta Pharmaceuticals2026-04-13 11:00 EST

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria

BNTXBioNTech2026-05-22 09:00 EST

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

GRIGRI Bio2026-04-08 08:30 EST

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

ENTAEnanta Pharmaceuticals2026-04-07 11:00 EST

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026

MLTXMoonLake Immunotherapeutics2026-05-10 13:00 EST

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

View all latest news

SOLIGENIX

Soligenix is a specialty biotechnology company focused on inflammatory diseases, biodefense, and orphan indications. Its story reflects a broad but still narrow small-cap pipeline targeting areas with high unmet need.

Recent company news

SNGXSOLIGENIX2026-06-08 11:30 EST

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

SNGXSOLIGENIX2026-05-26 11:30 EST

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

SNGXSOLIGENIX2026-05-08 11:30 EST

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

SNGXSOLIGENIX2026-04-28 11:30 EST

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

SNGXSOLIGENIX2026-04-02 11:30 EST

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

Stock data

Close: 0.36 USD
Market cap: 11.1M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States